Experts break down key kidney cancer data and trends from the 2026 ESMO Congress.
Feature|Articles|November 4, 2026
DLL3-Targeted Therapy and KRAS Inhibition Lead Lung Cancer Data Highlights From ESMO 2026
Author(s)OncLive Staff
Fact checked by: Ashling Wahner
Lung cancer experts outline some of the most crucial findings from ESMO 2026 that could affect future clinical decision-making.
Advertisement
Advertisement
As data emerged across the lung cancer treatment paradigm at the
Related to this article
Experts break down key gynecologic cancer data and trends from the 2026 ESMO Congress.
Rocbrutinib plus chemoimmunotherapy led to complete responses in patients with untreated B-cell lymphomas.
Misty D. Shields, MD, PhD, answers questions on ADCs, tarlatamab sequencing, first-line maintenance, subtyping, and transformed SCLC.
TP53 Comutations, Long-Term Toxicity, and Sunvozertinib Access Shape EGFR+ NSCLC Treatment Decisions
Faculty at an OncLive Scientific Interchange and Workshop discussed factors that help inform treatment selection in advanced EGFR-mutated NSCLC.
IBI363 plus bevacizumab extended progression-free survival vs docetaxel in patients with immunotherapy-resistant lung adenocarcinoma in a randomized phase 1b study.
Thoracic oncologists discuss HER2 testing, frontline treatment selection, and resistance mechanisms in HER2-altered non–small cell lung cancer.
Sac-TMT plus pembrolizumab prolonged PFS over chemoimmunotherapy in PD-L1–negative nonsquamous lung cancer.
Advertisement
Advertisement